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ABSTRACT
Neonatal abstinence syndrome is defined by signs and symptoms of withdrawal that infants
develop after intrauterine maternal drug exposure. All infants with documents in utero opioid
exposure, or a high pre-test probability of exposure should have monitoring with a standard
assessment instrument such as a Finnegan Score. A Finnegan score of >8 is highly correlated with
opioid exposure, even in the absence of declared use during pregnancy. At least half of infants in
most locales can be treated without the use of pharmacologic means. For this reason, symptom
scores will drive the decision for pharmacologic therapy. However, all infants, regardless of initial
manifestations, should be treated with non-pharmacologic approaches. Non-pharmacologic
approaches should not be considered an alternative to drug therapy, but instead the base upon
which all patients are treated. Those who continue to have symptoms should have addition of
pharmacologic treatment.
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Introduction
Neonatal abstinence syndrome (NAS) or neonatal opioid withdrawal syndrome is defined
by signs and symptoms of withdrawal that infants develop after intrauterine maternal drug
exposure [1]. Following the cessation of umbilical drug transfer, presentations include mild and
transient withdraw symptoms (nicotine, SSRIs) or toxidromes from direct drug effect (cocaine)
[2]. In contrast, prolonged in utero exposure to opioids is associated with a more specific and often
severe withdrawal syndrome [2]. The etiologic link has led to a proposed name of neonatal opioid
withdrawal syndrome (NOWS) rather than the more non-specific NAS [2]. As polydrug exposure,
particularly with concomitant benzodiazepines, is frequent and often leads to more
symptomatology, the term NAS remains more common in clinical practice [3]. The maternal dose
of methadone only weakly predicts severity of NAS symptoms [3]. The other clinical covariates
of NAS severity are similarly not particularly predictive, and actionable decisions are based
primarily on symptom presentation. Conceptually, the disease “NAS” captures a spectrum of
severity. Imprecision of descriptions often conflate a diagnosis of NAS only with a neonatal opioid
withdrawal that requires pharmacologic treatment. In fact, a more accurate approach is to define
NAS as cardinal symptoms of withdrawal in the setting of known or highly suspected opioid
exposure. NAS in whom pharmacologic therapy is used represent more severe disease. Most
newborns will develop withdrawal symptoms within 24-48 hours after birth, however, delayed
presentations of 5-10 days after birth are seen [4]. Severity and length of NAS might vary based
on gestational age, type of illicit drug, and when the substance was used last. Withdrawal
symptoms are graded using a standard instrument. The most commonly used are modifications of
the Finnegan Score, which was developed as a research tool in the 1970’s (Figure 1 for one variant
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known as MOTHER NAS score) [5], and once a certain Finnegan Score threshold is exceeded
newborns are treated [6, 7].

In the last 15 years, there has been a fivefold increase in NAS, which is associated with the
rise of opioid use during pregnancy [8]. The incidence of NAS in 2012 was estimated to be 6.0 per
1000 live US births - a 5-fold increase since 2000. Since 2012, the incidence has continued to
increase, with data in 2016 from 23 hospitals in the US Pediatric Health Information System
showing an incidence of 20 per 1000 live births [9]. This puts a heavy burden on health resources
since these newborns require prolonged medical treatment and longer hospital admission [10].

Treatment Approaches
All infants with documents in utero opioid exposure, or a high pre-test probability of
exposure should have monitoring with a standard assessment instrument such as a Finnegan Score.
A Finnegan score of >8 is highly correlated with opioid exposure, even in the absence of declared
use during pregnancy [11]. At least half of infants in most locales can be treated without the use
of pharmacologic means. We currently do not have good predictors of which infants will go on to
more severe disease. For this reason, symptom scores will drive the decision for pharmacologic
therapy. However, all infants, regardless of initial manifestations, should be treated with nonpharmacologic approaches. Non-pharmacologic approaches should not be considered an
alternative to drug therapy, but instead the base upon which all patients are treated. Those who
continue to have symptoms should have addition of pharmacologic treatment [Figure 1].

Non-pharmacological adjunct treatments
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Non-pharmacological management of NAS (Box 1) is the base used for all infants with in
utero opioid exposure [12, 13]. While specific interventions vary by location, ~95% of NICUs
offered some aspect of non-pharmacological care [12]. Many NAS symptoms cause
overstimulation in the newborn infant and non-pharmacological adjuncts utilize environmental and
behavioral approaches to maximize infant comfort. Mild cases of NAS (Finnegan Score <8) are
managed solely by using non-pharmacological approaches, while more severe cases require
treatment with medication. Common methods of non-pharmacological care include: swaddling,
positioning, quiet and dimly lit rooms, rooming-in, skin-to-skin contact, breastfeeding, and infant
positioning [14].

Environmental control
Environmental control including quiet and dimly lit rooms, swaddling, positioning, and
bed types are most commonly employed [14]. Adjusting environmental stimuli including sound
and lights can ensure that hyper-aroused infants who experience withdrawal are not over
stimulated.
Swaddling, a common practice which involves tightly wrapping the infant in a blanket, has
been shown to decrease arousal, prolong sleep, improve neuromuscular development, decrease
physiologic distress, improve motor organization, and self-regulatory ability [15]. While no study
has examined swaddling in infants with NAS, it is widely accepted as a safe, effective intervention.
The positive consequences of prone position for sleep include i) fewer awakenings and increased
time in quiet sleep, more sleep with higher arousal thresholds, lower levels of activity, enhanced
respiratory control, and diminished heart rate variability [16]. Maichuk et al randomized newborn
infants with NAS to prone position (n=24) or supine position (n=24) and demonstrated that the
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mean ±SD NAS was significantly higher in supine position compared prone position 7.6 ±0.7 vs
5.1 ±0.6 (p< 0.0001), respectively [16]. Also, supine-lying subjects had higher mean caloric intake
(133±11 kcal/kg/24h) compared to than prone-lying infants (100±9 kcal/kg/24h) (p<0.001) [16].
Prone positioning decreases NAS symptoms potentially due to the cardiorespiratory and
somatosensory effects of quieting response of prone positing [16]. Alternatively, non-oscillating
waterbeds provide vestibular and tactile stimulation that is dependent on the neonate’s own
activities and might decrease irritability and increases periods of sleep [17]. In addition, a nonoscillating water bed (n=15) had significant lower NAS scores, earlier onset of consistent weight
gain, and required up to 2mg/kg less phenobarbital compared to conventional bassinets (n=15)
[17]. In contrast, D'Apolito et al randomized 14 infants with NAS to either a mechanical rocking
bed or standard bed. Infants with the rocking bed therapy experienced a significant increase in
withdrawal symptoms, poorer sleep patterns, and decreased neurobehavioral functioning on day 7
of life in infants [mean ±SD NAS score of 10±2 compared to 8±2 (p=0.05)] [18]. These studies
suggest that prone position if possible combined with a non-oscillating water bed provides some
soothing effect to newborns with NAS.

Feeding methods
Breastfeeding is one of the most commonly used non-pharmacological interventions for
infants with NAS. However, there is often confusion about the safety of breastfeeding while on
opioid substitution therapy [19], because previous clinical guidelines proposed potential harmful
effects and from the possibility of continued concomitant illicit drug use [20]. While drugs are
present in breast milk of mothers on substitution therapy, concentrations are low with low oral
bioavailability, and no documented detrimental effects on infants [20]. Several studies analyzed
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the breast milk of mothers on methadone for substitution therapy and reported low concentration
of methadone in the breast milk not exceed 0.1mg/kg/day, amounting to only 2% of maternal dose
[21]. Opioid substitution therapy is not a contraindication to breastfeeding and most mothers on
substitution therapy should be encouraged to breastfeed [21, 22, 23].
Breastfeeding is consistently associated with a decrease in severity of NAS. A retrospective
chart review of 190 drug-dependent mother-infant-dyads showed reduced NAS severity within the
first 9 days and delayed onset, 25% reduction in need for pharmacologic treatment, and up to 20day decrease in lengths of pharmacologic treatment, regardless of the gestation and the type of
drug exposure when compared to formula fed [24]. Similarly, McQueen et al and Isemann et al
also reported reduction in mean NAS scores, duration of opioid treatment, and length of hospital
stay in breastfed infants [25, 26]. Welle-Strand et al reported a shorter mean ±SD lengths of stay
of 28.6±19 in breastfed infants (n=95) vs. 46.7±26 (p<0.05) in formula fed infants (n=29) exposed
to methadone, however no effect in infants exposed to buprenorphine was observed [27]. Despite
the obvious benefits of breast milk, breastfeeding rates remain low. Wachman et al reported that
only 24% of 276 opioid-exposed mother-infant-pairs at their baby-friendly hospital had any breast
milk during their hospital stay with 60% of them discontinuing after an average of 6 days [28].
Given the documented benefit, attempts should be made to minimize potential barriers and
increase breastfeeding rates in opioid-exposed infants.

Social integration
Parental presence might be beneficial due to rooming in or skin-to-skin contact, which
facilitates mother and infant bonding and maternal comforting of the infant. Several studies have
examined the effects of parental presences on NAS. Howard et al observed 86 mother-infant-dyads
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and reported that maximum parental presence (100%) was associated with a 9 day shorter lengths
of stay (r=-0.31) (p<0.01), an 8 day reduction of lengths of treatment (r=-0.34, p<0.001) and 1point decrease in mean NAS score (r=-0.35, p<0.01) [29]. Similar, Abrahams et al and Hodgson
et al examined the effects of rooming-in in infants exposed to maternal opioids in-utero [30, 31].
Infants in the rooming-in cohort had much higher breastfeeding rates (63% vs. 10% in nonrooming-in hospitals), it reduced morphine treatment (20-40% vs. 77% in non-rooming-in
hospitals), length of hospital stay, and admission rates to Level II NICUs [30, 31]. The major
benefit of rooming-in was the high rates of breast feeding mothers, which might have also
contributed to some of the observed benefits [32].

Acupuncture
Acupuncture might possibly work by the release of endogenous opioids which in turn help
restore the release of dopamine [33]. Illicit drugs can stimulate dopamine release and withdrawals
are characterized by low levels of dopamine which can be restored by acupuncture [33]. Laser
acupuncture is a form of non-invasive acupuncture that stimulates acupuncture points with use of
a low level laser beam [33]. Raith et al randomized 28 preterm and term infants and reported that
laser acupuncture combined with standard opioid treatment significantly decreases lengths of stay
from 50 (36-66) to 35 (25-47) days in the control and acupuncture group (p=0.19), respectively
[33]. Median (IQR) lengths of treatment was also significantly shorter with 28 (22-23) days for
the acupuncture group compared to 39 (32-48) days for the control group (p=0.48) [33].
Most non-pharmacological treatments (exception of rocking and outpatient therapy) are
safe, effective and easy to be implemented as adjuncts therapies to pharmacological treatments.
While generally low risk, such interventions do require staff time and attention for implementation,
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and as such a systemic evaluation of specific non-pharmacological therapies would assist
clinicians in directing time and effort toward high yield intervention while decreasing effort on
low yield efforts.

Pharmacological Treatments (Box 2)
The need for pharmacologic therapy is widely held to be needed for severe
symptomatology. This is commonly linked to a specific threshold on a score (often an 8 on a
Finnegan score) and less often explicitly linked to a goal of therapy. There is good consensus that
there is a subset of infants that require pharmacologic therapy, but less so in defining the goals of
care and tradeoffs associated with higher or lower threshold for treatment. Goals of pharmacologic
therapy are to relieve infant discomfort, allow proper nutrition and development, and to foster
parental bonding. End points in clinical trials are typically duration of therapy or length of
hospitalization. These trial endpoints are not necessarily congruent with the aforementioned goals
of treatment. For example, a higher threshold to start treatment and less aggressive dosing of an
infant could lead to fewer days of treatment, but at the cost of a more irritable infant, poor feeding
and weight gain, and parental stress. Similarly, attention is often paid to which is the best particular
drug, without recognition that the drug resides within a treatment protocol with specific initial
dose, up-titration schedule, maximum dose, and down titration. There have been few if any
comparative studies that examine different regimens within a specific drug. As full agonists,
morphine and methadone have a narrower therapeutic index than buprenorphine (partial agonist),
but with inpatient monitored use, there are very few short-term safety issues with any of the
commonly used opioids. With these caveats in mind, pharmacologic treatment is added when nonpharmacologic therapies adequately control NAS withdrawal symptoms. Cochrane and a variety
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of narrative reviews support the use of base therapy of an opioid, with the addition of an adjunctive
therapy. The opioid dose is increased until there is adequate control of symptoms, as defined using
a standardized symptom instrument such as the Finnegan. After a ~48 hours of stability, the dose
is slowly weaned. For those not fully controlled with an opioid alone, adjunctive drugs are added.
Specific regimens and doses vary between institutions, but a representative algorithm from Royal
Alexandra Hospital, Edmonton, Canada is presented in Figure 4.

Morphine
Morphine is acts as a full agonist on the  opioid receptors and morphine solution is one
of the most commonly used medications to treat NAS with ~80% of centers in the US employing
it as primary agent [4, 34]. There is heterogeneity in dosing approaches, titration rates and maximal
doses. The more common approach is that of weight based dosing, in which morphine is started at
a dose of 0.07 mg/kg every 4 hours once a specific score trigger is crossed, for example if an infant
has a Finnegan score >8 (Figure 3) [35]. An alternate approach is that the dose of morphine is not
adjusted for weight, and instead the initial dose is based only on the Finnegan score. A high score,
indicating severe disease, gets a high dose. The up titration is similar to the weight based approach,
but the dose is not adjusted for size of the infant. These two approaches have not been directly
compared to each other. Current recommendations for NAS treatment suggests oral morphine
solution should be diluted to a concentration of 0.4 mg/mL [36]. In addition, many pharmacies
have opted to use morphine over tincture of opium. Tincture of opium consists of opium 10mg/mL
and requires a 25-fold dilution to achieve the recommended 0.4 mg/mL morphine. Care must be
taken with dilution to avoid medical errors. Oral morphine is a preferred formulation. [36].
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Methadone
Methadone is a long acting mu opioid agonist, currently used in 20% of US centers. It also
has a NMDA antagonist effects, though how this may impact the clinical efficacy relative to
morphine, is unclear. Current evidence suggests that methadone has a modest advantage over
morphine based upon randomized controlled trials. (Table 1) The highest quality was that of Davis,
which was a multicenter, randomized, blinded trial of 116 term infants to either methadone or
morphine [39]. Compared to morphine, methadone treated infants had a significantly shorter mean
length of treatment 14.7 vs 16.6 days, and length of stay and 18.9 vs. 21.1 (p=0.02 and p=0.01),
respectively. A caveat to this trial was the use of a bespoke hybrid weight and symptom based
dosing regimen, which is not commonly employed. In addition, the trial used an alcohol free
formulation of methadone that is not commercially available. This may be difficult for some
hospital pharmacies to compound, though it is not expected that alcohol containing methadone
solutions should have any less efficacy than the one used in the trial. There is even greater
heterogeneity in methadone regimens than in morphine, and not a generally accepted standard
regimen. The development of specific regimens to date has been empiric and site specific.
However, modern pharmacometric modelled dosing regimens have demonstrated improved
outcomes [40]. Careful linking of pharmacokinetic data, a strict treatment protocol, and clearly
defined endpoints can generate of model that can be used to simulate new treatment regimens and
examine subpopulations. Refinements of these model-based approaches will likely lead to further
optimization of regimens. This approach has been piloted with methadone, but model building has
also been explored with morphine and buprenorphine [41,42,43].

Buprenorphine
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Buprenorphine is an emerging therapy for control of acute adult opioid withdrawal
symptoms and medically assisted opioid replacement therapies. It has a long half-life, which
allows once a day dosing. It is a partial  opioid agonist, which accounts for an excellent safety
profile relative to the full agonist methadone. Buprenorphine has been investigated as a primary
opioid for the pharmacologic treatment of NAS. Phase 1 studies investigated safety, dose finding,
and initial proof of concept [44,45]. These investigations were followed by a blinded, randomized
controlled trial comparing sublingual buprenorphine to oral morphine in 63 infants (the BBORN
trial). Buprenorphine had a shorter median length of treatment (15 vs. 28 days) and length of stay
(21 vs. 33 days) (both p<0.0001) [46]. Safety and need for adjunctive phenobarbital treatment was
similar in both groups. This therapeutic advantage was comparable to the phase 1 program (~35%
decreased length of treatment compared to morphine). In all these trials, the in utero exposure of
the infants was largely methadone. External validity of these single site, prospective trials is
provided by retrospective cohort data from 212 infants in the southern Ohio region. Infants treated
buprenorphine demonstrated a ~30% reduction in length of treatment compared to morphine and
methadone controls [47,48]. This was multicenter and infants had a more heterogeneous in utero
exposure of opioids and other drugs of abuse. The Ohio cohort employed the same buprenorphine
formulation, but did use a different treatment regimen (summarized in [49]).
Buprenorphine is administered sublingually in volumes of 0.5 mL or less, after which a pacifier is
inserted in the mouth and absorption likely complete within 2 minutes. The current ethanol
containing formulation is stable for 30 days in glass at room temperature and at least 7 days in
polypropylene-dispensing syringes [50]. The ethanol provides asepsis and stability of the solution,
and may promote absorption (though this has not been formally tested). Questions about the safety
of the ethanol content has been raised [51]. The ethanol exposure seen in infants in the BBORN
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trial were all lower than 7 mg/dL. The American Academy of Pediatrics guidance suggests a peak
concentration of less than 25 mg/dL after administration of an ethanol containing medication [52]

Non-opioid Adjunct Therapy
The two agents used as adjuncts are the centrally acting alpha 2 adrenergic agonist
clonidine and the GABA agonist phenobarbital. There have been a number of small studies which
have compared an adjunct to an opioid. The ideal adjunct therapy or regimen has not been defined.
The treatment approaches in which adjuncts are used are listed in Figure 3. In current use, adjuncts
can be given only when symptoms are not controlled and weaned before cessation of the opioid.
Other centers will wean the opioid first, and discontinue the adjunct later as an inpatient or
outpatient. This approach is much more common for phenobarbital than clonidine. The third
approach is that of parallel opioid and clonidine therapy, with a goal of reducing opioid exposure
was well as length of treatment.

Clonidine
Clonidine has inhibitory effects on the release of noradrenaline which leads to a decrease
in withdrawal symptoms [53]. In adults it is used for reduction of acute opioid withdrawal
symptoms, but not chronic management of opioid use disorder. The highest quality evidence of
efficacy in NAS is that of a randomized controlled trial of Agthe et al (n= 80). Clonidine added to
the standard opioid treatment reduced diluted tincture of opium/kg per day compared to the
placebo (p<0.03) and improved median length of therapy compared to placebo (11 vs 15 days, P
= 0.02) [54]. Twelve percent of the infants in the placebo group had treatment failure while there
were none in the clonidine group. A second unblinded RCT (n=68) by Surran that was stopped
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early compared clonidine to phenobarbital on a base of morphine treatment. Phenobarbital had
18.2 and clonidine 13.6 days of opioid treatment (p= 0.037) [55]. Clonidine was stopped before
discharge while infants were sent home on phenobarbital, often for months. The doses of both
adjuncts were also high. A prospective pilot study of Bada (n= 31) compared clonidine vs.
morphine as primary treatment. Clonidine has shorter median length of treatment (28 compared to
39 days). Though there were early differences in NICU Network Neurobehavioral Scale (NNNS)
summary scores, at one year cognitive, motor and language scores did not differ between the
groups [56] In adults, clonidine has less sedation than phenobarbital, but is subject to rebound
hypertension with rapid cessation. In the inpatient setting, the side effect profile of clonidine has
been reassuring.

Phenobarbital
Phenobarbital is a drug widely used for the treatment of non-opioid NAS, as well as
commonly used in the NICU as an antiepileptic. Most common use is as an adjunct to an opioid.
While described as and effective alternative to an opioid as base therapy, [57] the overwhelming
current use is that as adjunct to an opioid when symptoms become severe. At what point
phenobarbital is added is more variable between sites than that seen with clonidine. A common
approach is to add when the maximal dose of the opioid is reached. Another approach is to add
early, when the velocity of symptom change will suggest more severe NAS presentation [58]. In a
partially randomized study of 20 infants, Coyle described decreased mean lengths of stay 79 vs 38
days when phenobarbital was added to diluted tincture of opium (p <0.001) [59]. The long length
of stay from this 2002 and likely different modes of non-pharmacologic treatment at the time make
direct comparisons to current care less clear. However, the general vector of decreased opioid use
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with addition of phenobarbital is clear. A concern limited more widespread use of phenobarbital
early on is that of safety and long term neurodevelopment. The product label states use has been
associated with cognitive deficits in children taking for seizures, and animal models of long term
behavioral outcome are also of potential concern [60]. The issue of potential bias by indication for
a seizure population makes direct comparisons to infants with NAS difficult. Long term
neurodevelopmental outcome studies of infants treated for NAS are subject to occult bias due to
the in utero opioid exposure, opioid used to treat NAS, and most importantly the environment the
infant is raised in which make comparisons to non-phenobarbital exposed controls problematic.
The widespread use of phenobarbital in the NICU, familiarity of clinicians with use, and lack of
clear evidence of toxicity have led to continued use as an adjunct in NAS. Whereas clonidine has
a mechanism of action more specific to opioid withdrawal, phenobarbital has a more global
sedative effect which may provide added efficacy in circumstances of poly-substance exposure.

Treatment Location
Pharmacologic treatment is most commonly administered in the inpatient setting. There
have been a number of sites that transition pharmacologic treatment to the outpatient setting.
Opioids, particularly the long acting agent methadone, has been used in the outpatient setting.
More commonly, the opioid is weaned during the inpatient stay or soon after discharge with
phenobarbital being the primary pharmacologic therapy. Any attempt to transition treatment to the
outpatient setting requires a robust follow up mechanism and outpatient pediatricians familiar and
comfortable with managing an outpatient wean. Compared to outpatient weaning, the use of
inpatient pharmacologic treatment is consistently reported as being associated with longer lengths
of hospitalization, but shorter total duration of treatment [61]. The best documented experience is
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a population based retrospective cohort study of 532 infants reported infants. Consistent with prior
studies, the median (IQR) length of pharmacological therapy was significant shorter in inpatients
compared to outpatients 19 (10-31) days vs. 60 (38-92) days; p<0.001) [62]. Infants treated as
outpatients had have an increased number of emergency room visits within 6 months of discharge
(adjusted odds ratio 1.52, 95% CI 1.06-2.17) when compared with those treated as inpatients alone
[62]. While not statistically significant, the point estimate odd ratio for emergency visit at 6 weeks,
or any hospitalization at 6 or 24 weeks was ~1.5 for outpatient compared to inpatient treatment.
Most (82%) were treated with phenobarbital alone. These data suggest caution when considering
transition to outpatient treatment, and only in circumstances where there is a comprehensive
support structure to safely manage these infants.

Discussion
Non-Pharmacological treatment is the base therapy that should be administered to all
infants with in utero exposure to opioids. Non-pharmacological treatments are safe, effective, and
can be easy implemented. Interventions will vary by the ability of a site provide based upon
physical layout, structure of maternal treatment, and staffing considerations. There has been
examination of the relative merit of each specific element, but the evidence base upon which to
evaluate interventions remains low. The issue is not one of safety, but instead from a menu of
many non-pharmacologic interventions, infants and institutions will be best served if high impact
interventions are chosen over lower. Future needs include standardized descriptions of
interventions and comparative evaluation between them. Given the large matrix of possible
combinations, a reasonable approach is to instead focus on comparisons of bundles with
differentiation focused on high resource intensive activities. These would not necessarily need to
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be randomized controlled trials but could be quality improvement initiatives or pragmatic
investigations built into standard of care using electronic medical records.
Pharmacological intervention is a cornerstone in achieving growth and symptom control in
severe NAS. Recent years have seen the emergence of high quality evidence to refine choices. The
choice of a specific agent is important, but not the only predictor of success. The treatment regimen
within which the drug resides is a key consideration. Weight vs. symptom based dosing is just one
area that would benefit from investigation. Newer modeling tools such a pharmacometrics hold
promise in optimizing dose selection. A pharmacokinetic/pharmacodynamic model does not
guarantee to identify the ideal dose, but it is significantly more likely to do so than the old method
of intuition or hunch-based empiric regimen creation. Pharmacogenetic differences and disease
expression and response to treatment may be helpful eventually, but this tool for NAS remains in
the discovery phase and far from providing actionable decisions. The use of an opioid as primary
therapy is settled practice. What agent, doses, titration schema, as well and when to start an adjunct,
which one, and how to wean all are areas under current investigation.

Practice points
•

Non-pharmacological treatments are safe, effective, and can be easy implemented.

•

Interventions will vary by the ability of a site provide based upon physical layout, structure of
maternal treatment, and staffing considerations.

•

The need for pharmacologic therapy is widely held to be needed for severe symptomatology.

•

This is commonly linked to a specific threshold on a score (often an 8 on a Finnegan score)
and less often explicitly linked to a goal of therapy.
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•

There is good consensus that there is a subset of infants that require pharmacologic therapy,
but less so in defining the goals of care and tradeoffs associated with higher or lower threshold
for treatment.

•

Goals of pharmacologic therapy are to relieve infant discomfort, allow proper nutrition and
development, and to foster parental bonding.

Research agenda
•

Future studies of non-pharmacological intervention should include standardized descriptions
of interventions and comparative evaluation between them. Furthermore, given the large
matrix of possible combinations, a reasonable approach is to instead focus on comparisons of
bundles with differentiation focused on high resource intensive activities.

•

Future studies of pharmacological intervention should examine what agent, doses, titration
schema, as well and when to start an adjunct, which one, and how to wean. In addition, longterm outcomes should be addressed in any future studies.
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Figure 1: Representative Modified Finnegan Score (MOTHER NAS score)
Signs and Symptoms
Crying
Sleeps

Moro Reflex
Tremors: Disturbed
Tremors: Undisturbed
Increased Muscle Tone

Excoriation
Generalized Seizure
Fever > 37.3 C (99.2 F)
Frequent Yawning
Sweating
Nasal Stuffiness
Sneezing (4 or more successive times)
Tachypnea
Poor feeding
Vomiting (or regurgitation)
Loose Stools
Failure to thrive
Excessive Irritability

Severity
Excessive high pitched
Continuous high pitched
< 1 hours after feeding
< 2 hours after feeding
< 3 hours after feeding
Hyperactive
Markedly Hyperactive
Hands or feet only, up to 3 seconds
Arms or legs, over 3 seconds
Hands or feet only, up to 3 seconds
Arms or legs, over 3 seconds
Difficult but possible to straighten arm and head
lag present
Unable to straighten arm and head lag absent
Skin is red but intact or healing
Skin not intact

>4 or more successive times

>4 or more successive times
Respiratory Rate >60/mm

Diaper is > half liquid/half solid
Current weight > 10% below birth weight
Consoling calms infant in <5 min
Consoling calms infant in 6-15 min
Inconsolable
Summed Score
Recorded, unscored elements
Convulsions
Fever > 38.4 C (101.2 F)
Mottling
Excessive sucking
Watery Stools
Projectile vomiting
Retractions
Nasal flaring
Myoclonic jerks

Score
2
3
3
2
1
1
2
1
2
1
2
1
2
1
2
8
1
1
1
1
1
2
2
2
2
2
1
2
3
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Figure 2: Approach to infants with in utero opioid exposure. All infants should be provided a base of non-pharmacologic therapies.
Specific measures will vary with the ability of the local site to provide. Some potential approaches are listed. Pharmacologic therapy is
added only in those for whom symptoms are not controlled with non-pharmacologic means.

NAS Severity
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Figure 3: Role of Adjunctive Therapies. The optimal use of adjunctive therapy with an opioid has not been defined. (A) An adjunct is
used only when symptoms are severe and the adjunct is weaned before the opioid. (B) The adjunct is started in those not controlled
with an opioid, but the adjunct is continued after the opioid is weaned, sometimes in an outpatient setting. (C) The adjunct serves as an
opioid sparing agent which is started and stopped at the same time as the opioid.

A

B

C
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Figure 4: NAS Treatment Flowchart at the Royal Alexandra Hospital, Edmonton, Canada
Confirmed or suspected maternal opioid use during pregnancy

Bedside nurse to begin NAS scoring every 4 hours and adjust frequency as directed by site specific scoring tool

Scores consistently less than 8 are managed by
supportive measures

Prescriber to initiate pharmacologic therapy additionally to
supportive measures:
- 3 consecutive scores of 8 or greater
- Average of 3 consecutive scores is 8 or greater
- Average of 2 consecutive scores of 12 or greater

INITIATION PHASE: Start oral morphine 50 ug/kg/dose q3H and continue NAS scoring

Newborn has been on morphine for 12 hours and
continues to have 2 or more consecutive scores greater
than or equal to 8
STABILIZATION PHASE: All scores remain
less than 8 for 48 hours while on morphine
therapy

ESCALATION PHASE:
Increase dose by 15 mcg/kg/dose at 6 hour intervals until scores less
than 8. Keep dose frequency q3H.
NOTE: If morphine total daily dose is greater than 1000 ug/kg/day and
scores remain over 8 consider adding an adjunctive treatment (A2)

WEANING PHASE:
Once stabilized on same dose for 48 hours, use this dose as starting point of wean.
Wean the dose by 10% of the total daily amount of the stabilization dose. Do not make dose changes more frequently than every
24-72 hours as tolerated.
If newborn is on morphine and an adjunct, wean off morphine first.
If scores consistently less than 8, continue to
If newborn has 2 consecutive scores greater than 8, go back to previous
decrease dose by 10% of the total daily amount of
dose at which newborn was stable. If unable to keep scores less than 8
the stabilization dose. Consider extending dosing
despite changing to previous dose, go back to escalation phase.
interval to every 4 hours depending on newborn’s
feeding schedule.

Discontinue morphine when scores are less than 8
at 20 ug/kg/dose. Continue NAS scoring for 48
hours after discontinuation.

Newborn requires oral morphine for discharge (weaning will happen as
an outpatient).
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Table 1: Methadone vs. Morphine: Studies in which morphine and methadone were compared for
median length of treatment.
Author

Design

N

Morphine

Methadone

P

Lainwala [64]

2005

Retrospective

46

36

40

>0.05

Hall [40]

2014

Retrospective

383

16*

16*

NS

Young [65]

2015

Retrospective

26

7*

38*

0.001

Brown [63]

2015

Blinded RCT

31

21

14

0.008

Davis [39]

2018

Blinded RCT

183

15

11.5

0.02

*= mean, RCT = randomized controlled trial
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Box 1: Non Pharmacological Adjunct Treatments for Neonatal Abstinence Syndrome
Non Pharmacological Adjunct Treatments
Environmental control
• Room lighting
• Swaddling
• Positioning
• Bed types
Feeding methods
• Breastfeeding
• Formula feeding
Social Integration
• Parental rooming in
• Skin to Skin contact
Treatment Location
• Inpatient vs Outpatient
Acupuncture
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Box 2: Pharmacological Treatments for Neonatal Abstinence Syndrome
Pharmacological Treatments for NAS
Opioid
• Morphine
• Methadone
• Buprenorphine
Non-opioid Adjunct Therapy
• Clonidine
• Phenobarbital
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